CRISM Therapeutics Corporation
AMMCF
$6.77
$6.573,309.57%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 60.26% | 60.26% | -372.83% | -372.83% | -- |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 81.39% | 74.62% | 1,269.88% | 1,269.88% | -- |
| Change in Net Operating Assets | -- | -- | -- | -- | -- |
| Cash from Operations | 71.37% | 66.70% | -48.57% | -48.57% | -- |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3,189.51% | -- | -- | -- | -- |
| Cash from Investing | 282.91% | 560.28% | 10,497.55% | 10,497.55% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -272.87% | -- | -8,590.72% | -8,590.72% | -- |
| Foreign Exchange rate Adjustments | -- | 289.47% | 81.58% | 81.58% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -59.74% | -35.02% | 292.23% | 292.23% | -- |
